TScan Therapeutics Statistics
Total Valuation
TCRX has a market cap or net worth of $9.66 million. The enterprise value is $25.90 million.
Important Dates
The last earnings date was Thursday, November 12, 2026, before market open.
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
TCRX has 67.78 million shares outstanding. The number of shares has increased by 19.44% in one year.
| Current Share Class | 63.50M |
| Shares Outstanding | 67.78M |
| Shares Change (YoY) | +19.44% |
| Shares Change (QoQ) | +91.84% |
| Owned by Insiders (%) | 0.18% |
| Owned by Institutions (%) | 62.03% |
| Float | 54.36M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.90 |
| Forward PS | 5.27 |
| PB Ratio | 0.26 |
| P/TBV Ratio | 0.26 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 5.03 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.03, with a Debt / Equity ratio of 2.35.
| Current Ratio | 2.03 |
| Quick Ratio | 1.93 |
| Debt / Equity | 2.35 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -39.97 |
Financial Efficiency
Return on equity (ROE) is -126.45% and return on invested capital (ROIC) is -39.01%.
| Return on Equity (ROE) | -126.45% |
| Return on Assets (ROA) | -35.47% |
| Return on Invested Capital (ROIC) | -39.01% |
| Return on Capital Employed (ROCE) | -110.56% |
| Weighted Average Cost of Capital (WACC) | 3.36% |
| Revenue Per Employee | $37,580 |
| Profits Per Employee | -$833,964 |
| Employee Count | 138 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -86.81% in the last 52 weeks. The beta is 1.19, so TCRX's price volatility has been higher than the market average.
| Beta (5Y) | 1.19 |
| 52-Week Price Change | -86.81% |
| 50-Day Moving Average | 0.25 |
| 200-Day Moving Average | 0.80 |
| Relative Strength Index (RSI) | 28.09 |
| Average Volume (20 Days) | 463,049 |
Short Selling Information
The latest short interest is 2.02 million, so 2.98% of the outstanding shares have been sold short.
| Short Interest | 2.02M |
| Short Previous Month | 2.28M |
| Short % of Shares Out | 2.98% |
| Short % of Float | 3.72% |
| Short Ratio (days to cover) | 3.61 |
Income Statement
In the last 12 months, TCRX had revenue of $5.19 million and -$115.09 million in losses. Loss per share was -$1.71.
| Revenue | 5.19M |
| Gross Profit | -107.36M |
| Operating Income | -114.52M |
| Pretax Income | -115.09M |
| Net Income | -115.09M |
| EBITDA | -111.73M |
| EBIT | -114.52M |
| Loss Per Share | -$1.71 |
Full Income Statement Balance Sheet
The company has $73.04 million in cash and $89.28 million in debt, with a net cash position of -$16.24 million or -$0.24 per share.
| Cash & Cash Equivalents | 73.04M |
| Total Debt | 89.28M |
| Net Cash | -16.24M |
| Net Cash Per Share | -$0.24 |
| Equity (Book Value) | 38.01M |
| Book Value Per Share | 0.56 |
| Working Capital | 38.97M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$110.89 million and capital expenditures -$775,000, giving a free cash flow of -$111.67 million.
| Operating Cash Flow | -110.89M |
| Capital Expenditures | -775,000 |
| Depreciation & Amortization | 2.79M |
| Net Borrowing | n/a |
| Free Cash Flow | -111.67M |
| FCF Per Share | -$1.65 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | -2,208.27% |
| Pretax Margin | -2,219.19% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TCRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -19.44% |
| Shareholder Yield | -19.44% |
| Earnings Yield | -1,197.34% |
| FCF Yield | -1,135.44% |
Analyst Forecast
The average price target for TCRX is $1.00, which is 601.75% higher than the current price. The consensus rating is "Hold".
| Price Target | $1.00 |
| Price Target Difference | 601.75% |
| Analyst Consensus | Hold |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 10.95% |
| EPS Growth Forecast (3Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |